Docs, drugmakers conspire on lucrative new doses of old meds: NYT

Behind the usual pharma scenes is a network of doctors, small drugmakers and distributors hawking new dosages of old drugs, a practice that allows physicians to dispense them and reap the profits by billing insurers directly. States have tried to crack down on physician dispensing, but doctors and companies have found loopholes and devised new ways to stay ahead of the law, The New York Times reports. Story (sub. req.)

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.